(MedPage Today) — The 2022-2023 nationwide shortage of stimulant medications for attention deficit-hyperactivity disorder (ADHD) may have been driven by international supply chain disruptions rather than overprescribing, an economic evaluation…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
